Pfizer Presents Optimistic Information from Section 2 Examine of Ponsegromab in Sufferers with Most cancers Cachexia By Investing.com
Examine met main endpoint of change from baseline in physique weight for…
Moberg Pharma lowers expectations on main endpoint in ongoing section 3 trial following information in a subset of sufferers By Investing.com
STOCKHOLM, Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) broadcasts…
Longboard Prescription drugs Broadcasts Optimistic Interim Evaluation Outcomes from the Open-Label Extension (OLE) of the Part 1b/2a PACIFIC Examine Evaluating Bexicaserin in Members with Developmental and By Investing.com
Bexicaserin achieved an general median seizure discount of 57.7% in countable motor…
Ifinatamab Deruxtecan Continues to Display Promising Goal Response Charges in Sufferers with Intensive-Stage Small Cell Lung Most cancers in IDeate-Lung01 Part 2 Trial By Investing.com
Goal response price of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab…
Yunovia Pronounces IND Approval by the MFDS to Provoke Section 1 MAD Examine for the Small Molecule GLP-1 Agonist By Investing.com
SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D…
Research outcomes from section 1 research with exidavnemab printed in The Journal of Medical Pharmacology By Investing.com
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA…
atai stories constructive Part 1b outcomes for despair remedy By Investing.com
NEW YORK and BERLIN – atai Life Sciences (NASDAQ: ATAI), a biopharmaceutical…
Senhwa Biosciences receives US FDA Examine Might Proceed letter for the Part I/II examine of Silmitasertib (CX-4945) together with chemotherapy in kids and younger adults with relapsed refractory s By Investing.com
TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc.…
US targets nitrous oxide in new part of local weather struggle By Reuters
(This July 23 story has been corrected to repair the spelling of…
Outcomes from Anavex Life Sciences Landmark Part IIb/III Trial of Blarcamesine Introduced at Alzheimer’s Affiliation Convention By Investing.com
Oral, as soon as day by day blarcamesine considerably slowed scientific decline…
